Sun Pharmaceutical Industries First Quarter 2026 Earnings: Revenues Beat Expectations, EPS Lags

Sun Pharmaceutical Industries (NSE:SUNPHARMA) First Quarter 2026 Results

Key Financial Results

• Revenue: ₹138.5b (up 9.5% from 1Q 2025).
• Net income: ₹22.8b (down 20% from 1Q 2025).
• Profit margin: 17% (down from 22% in 1Q 2025). The decrease in margin was driven by higher expenses.
• EPS: ₹9.50 (down from ₹11.80 in 1Q 2025).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Sun Pharmaceutical Industries Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) missed analyst estimates by 22%.

Looking ahead, revenue is forecast to grow 9.3% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India.

Performance of the Indian Pharmaceuticals industry.

The company's shares are down 3.6% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 1 warning sign for Sun Pharmaceutical Industries that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.